6. Parkinson disease
2,123 clinical trials,   2,046 drugs   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways

Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03575195
(ClinicalTrials.gov)
July 15, 201921/6/2018Microbiota Intervention to Change the Response of Parkinson's DiseaseMicrobiota Intervention to Change the Response of Parkinson's DiseaseParkinson DiseaseDrug: Rifaximin;Other: PlaceboUniversity of California, San FranciscoNova Southeastern University;Gateway Institute for Brain ResearchRecruiting30 YearsN/AAll86Phase 1;Phase 2United States
2NCT03958708
(ClinicalTrials.gov)
May 13, 201914/5/2019Modulation of Gut Microbiota by Rifaximin in PD PatientsModulation of Gut Microbiota by Rifaximin in PD PatientsParkinson Disease;InflammationDrug: Rifaximin 550 MGTaipei Medical University Shuang Ho HospitalNULLRecruiting45 Years70 YearsAll20Phase 1;Phase 2Taiwan
3NCT02470780
(ClinicalTrials.gov)
December 20154/6/2015Treating Bacterial Overgrowth in Parkinson's DiseaseTreating Bacterial Overgrowth in Parkinson's DiseaseParkinson's Disease;Small Intestinal Bacterial OvergrowthDrug: Rifaximin;Drug: PlaceboUniversity of CincinnatiNULLCompleted18 YearsN/AAll24Phase 2;Phase 3United States
4NCT01662791
(ClinicalTrials.gov)
September 20127/8/2012Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial OvergrowthWeight Loss in Parkinson's Disease and the Potential Role of Small Bowel Bacterial OvergrowthParkinson's DiseaseDrug: RifaximinMayo ClinicNULLCompleted18 YearsN/AAll49Phase 3United States